In addition, existing anti‐IL‐6R antibody therapies used in the clinic (and for that matter, also those against IL‐6), such as tocilizumab and sarilumab, block both protective (i.e., classic) and pathological (i.e., trans) signaling activities of IL‐6, causing side effects such as compromised host defense against bacteria (i.e., infections), imbalanced metabolism leading to higher blood cholesterol and triglyceride levels, and increased risk of gastrointestinal tract perforations (Rose‐John et al, 2017; Jones & Jenkins, 2018). Here, IL6 is linked to infection.